SCHEMBL3017975

SCHEMBL3017975

Cc1cc(C)c(S(=O)(=O)N2CCN(c3nc(Cc4cc(F)cc(Cl)c4)cs3)CC2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.37
MEN1 O00255 1/20 0.37
EPHX2 P34913 4/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.36
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651999 0.93 LMNA (0.40) KDM4ENPSR1TSHRLMNAALDH1A1
SCHEMBL3004672 0.93 NPSR1 (0.43) KDM4ENPSR1TSHRLMNAALDH1A1
SCHEMBL3013128 0.93 KDM4E (0.44) KDM4ENPSR1TSHRALDH1A1KMT2A
SCHEMBL3652504 0.92 KDM4E (0.43) KDM4ENPSR1TSHRALDH1A1KMT2A
SCHEMBL3009422 0.91 KMT2A (0.40) KDM4ENPSR1LMNAALDH1A1SMN1; SMN2
SCHEMBL3022517 0.89 SMN1; SMN2 (0.41) KDM4ELMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3020021 0.87 NPSR1 (0.47) KDM4ENPSR1TSHRLMNAALDH1A1
SCHEMBL3021968 0.87 ALDH1A1 (0.49) KDM4ENPSR1TSHRLMNAALDH1A1
SCHEMBL3006920 0.87 LMNA (0.42) KDM4ENPSR1TSHRLMNAALDH1A1
SCHEMBL3008378 0.87 EPHX2 (0.47) KDM4ENPSR1TSHRLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM4E 4398/4885NPSR1 764/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.